Current and novel approaches to the drug therapy of obesity

被引:17
作者
Chaput, Jean-Philippe [1 ]
Tremblay, Angelo [1 ]
机构
[1] Univ Laval, Fac Med, Dept Social & Prevent Med, Div Kinesiol, Ste Foy, PQ G1K 7P4, Canada
基金
加拿大健康研究院;
关键词
pharmacotherapy; sibutramine; orlistat; endocannabinoid receptors; leptin; ghrelin; adipokines; lipin inhibitor;
D O I
10.1007/s00228-006-0186-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Obesity has been described as the greatest current threat to human health. Although diet and lifestyle changes remain the cornerstones of therapy for obesity, weight losses are often small, and long-term success is disappointing. Discussion: When these lifestyle-modifying attempts fail, the use of anti-obesity drugs is warranted. Drug treatment is often indicated, but is somewhat limited by the minimal number of well-tolerated drugs that have proven to have long-term efficacy in maintaining body weight loss. The currently available drugs, sibutramine and orlistat, appear modestly effective in promoting weight loss. However, pharmacological therapy for obesity is in transition; expanding knowledge of the physiological mechanisms of body weight regulation has revealed new molecular targets, and more than 150 novel agents are under active development. Conclusions: Because weight regulation is complex, and redundant systems protect against perceived starvation, optimal treatment of obesity will likely require combinations of therapies. In addition, a better comprehension of the problem prior to its treatment would be preferable before targeting homeostatic pathways which could be irrelevant.
引用
收藏
页码:793 / 803
页数:11
相关论文
共 91 条
[1]   CANNABIS - EFFECTS ON HUNGER AND THIRST/EUM OF [J].
ABEL, EL .
BEHAVIORAL BIOLOGY, 1975, 15 (03) :255-281
[2]   Decreased plasma adiponectin concentration in patients with essential hypertension [J].
Adamczak, M ;
Wiecek, A ;
Funahashi, T ;
Chudek, J ;
Kokot, F ;
Matsuzawa, Y .
AMERICAN JOURNAL OF HYPERTENSION, 2003, 16 (01) :72-75
[3]   Role of leptin in the neuroendocrine response to fasting [J].
Ahima, RS ;
Prabakaran, D ;
Mantzoros, C ;
Qu, DQ ;
Lowell, B ;
MaratosFlier, E ;
Flier, JS .
NATURE, 1996, 382 (6588) :250-252
[4]   Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes [J].
Ahrén, B ;
Simonsson, E ;
Larsson, H ;
Landin-Olsson, M ;
Torgeirsson, H ;
Jansson, PA ;
Sandqvist, M ;
Båvenholm, P ;
Efendic, S ;
Eriksson, JW ;
Dickinson, S ;
Holmes, D .
DIABETES CARE, 2002, 25 (05) :869-875
[5]  
ALBU J, 2003, CLIN OFFICE PRACT, V30, P465, DOI DOI 10.1016/S0095-4543(03)00043-5
[6]  
ANTHENELLI RM, 2004, SESS LAT BREAK CLIN
[7]   Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity [J].
Arita, Y ;
Kihara, S ;
Ouchi, N ;
Takahashi, M ;
Maeda, K ;
Miyagawa, J ;
Hotta, K ;
Shimomura, I ;
Nakamura, T ;
Miyaoka, K ;
Kuriyama, H ;
Nishida, M ;
Yamashita, S ;
Okubo, K ;
Matsubara, K ;
Muraguchi, M ;
Ohmoto, Y ;
Funahashi, T ;
Matsuzawa, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (01) :79-83
[8]  
Astrup A, 1998, INT J OBESITY, V22, pS30
[9]   Correlation between serum resistin level and adiposity in obese individuals [J].
Azuma, K ;
Katsukawa, F ;
Oguchi, S ;
Murata, M ;
Yamazaki, H ;
Shimada, A ;
Saruta, T .
OBESITY RESEARCH, 2003, 11 (08) :997-1001
[10]   Absence of cardiac valve dysfunction in obese patients treated with sibutramine [J].
Bach, DS ;
Rissanen, AM ;
Mendel, CM ;
Shepherd, G ;
Weinstein, SP ;
Kelly, F ;
Seaton, TB ;
Patel, B ;
Pekkarinen, TA ;
Armstrong, WF .
OBESITY RESEARCH, 1999, 7 (04) :363-369